Company intelligence / Profile preview

Nuron

Exton, Pennsylvania, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Nuron Biotech's lead drug candidate NU100 (interferon beta-1b) was in Phase 3 clinical trials for multiple sclerosis treatment, with the potential to improve long-term clinical efficacy, tolerability and safety compared to existing interferon therapies.

Therapeutic areas: NeurologyInfectious Diseases
Modalities: VaccineRecombinant protein
Industry: Biotech

Partnerships

HealthCare Royalty Partners (financing partner)

Beyond the preview

Go deeper on Nuron.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuron.

Explore the full profile